Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. META
2. NVDA
3. SPY
4. USO
5. VRTX
6. LGND
7. ONON
8. VKTX
9. DCOY
10. GS

Go back to Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
(NASDAQ: QNRX) Delayed: 7.10 +0.20 (2.90%)
Previous Close $6.90    52 Week High $ 
Open $6.98    52 Week Low $ 
Day High $7.16    P/E N/A 
Day Low $6.91    EPS $ 
Volume 23,552